Trials / Unknown
UnknownNCT04708158
Novaferon for COVID-19 Treatment Trial (NCTT-005)
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Aerosolized Novaferon vs. Placebo in Hospitalized Adult Patients With ModerateCOVID-19
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 385 (estimated)
- Sponsor
- Genova Inc. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Novaferon | a novel recombinant antiviral protein drug |
| BIOLOGICAL | Placebo | Saline |
Timeline
- Start date
- 2021-03-25
- Primary completion
- 2023-04-30
- Completion
- 2023-04-30
- First posted
- 2021-01-13
- Last updated
- 2022-01-28
Locations
22 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04708158. Inclusion in this directory is not an endorsement.